ImmuCell Corporation provided earnings guidance for first quarter ending March 31, 2023. For the period, the company expects to report reduced sales during the first quarter of 2023 and a large, increased backlog as of March 31, 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.27 USD | -3.12% | +3.54% | +3.54% |
09/04 | Immucell Corporation Reports Unaudited Sales Results for the Three Months and Twelve Months Ended March 31, 2024 | CI |
02/04 | ImmuCell Shares Fall After $20 Million Mixed Securities Shelf Filing | MT |
1st Jan change | Capi. | |
---|---|---|
+3.54% | 4.12Cr | |
+30.30% | 4.82TCr | |
-0.05% | 4.17TCr | |
+43.17% | 4.1TCr | |
-5.31% | 2.88TCr | |
+10.87% | 2.56TCr | |
-22.02% | 1.9TCr | |
+9.26% | 1.29TCr | |
+28.58% | 1.2TCr | |
-2.64% | 1.18TCr |
- Stock Market
- Equities
- ICCC Stock
- News ImmuCell Corporation
- Immucell Corporation Provides Earnings Guidance for First Quarter Ending March 31, 2023